MIST Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

2.100

Open

2.090

VWAP

2.03

Vol

1.05M

Mkt Cap

247.10M

Low

1.980

Amount

2.13M

EV/EBITDA(TTM)

--

Total Shares

117.67M

EV

198.33M

EV/OCF(TTM)

--

P/S(TTM)

113.83

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.

Show More

Events Timeline

(ET)

2026-04-10

08:11:00

Milestone Pharmaceuticals Announces Cardamyst Study Plan

2026-03-31 (ET)

2026-03-31

08:11:00

Milestone Pharmaceuticals' Cardamyst Nasal Spray Added to National Formularies

2026-03-20 (ET)

2026-03-20

16:20:00

Major Averages Close Broadly Lower, S&P 500 Down Over 1.5%

2026-03-20

12:10:00

Major Averages Decline Again as Oil Prices Rise

2026-03-20

09:00:00

Stock Futures Modestly Lower, Market Sentiment Cautious

2026-03-20

07:20:00

Milestone Cash and Short-Term Investments Rise to $106M

2026-03-16 (ET)

2026-03-16

08:20:00

Milestone Pharmaceuticals to Showcase New Treatment at ACC 2026

2026-02-10 (ET)

2026-02-10

08:30:00

Milestone Appoints David Sandoval as General Counsel

News

Newsfilter

04-10Newsfilter

Milestone Pharmaceuticals Launches CARDAMYST Registry Study

NASDAQ.COM

03-23NASDAQ.COM

Milestone Pharmaceuticals Reports Q4 and FY 2025 Results with CARDAMYST Updates

Newsfilter

03-20Newsfilter

Milestone Pharmaceuticals Earnings Report Preview

Yahoo Finance

03-20Yahoo Finance

Milestone Pharmaceuticals Reports Q4 2025 Earnings and CARDAMYST Launch

seekingalpha

03-20seekingalpha

Milestone Pharmaceuticals Reports FY Results

seekingalpha

03-19seekingalpha

Major Earnings Reports Expected on Friday

3 Analyst Rating

Wall Street analysts forecast MIST stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

Raymond James

Strong Buy

initiated

$6

AI Analysis

2026-04-10

Reason

Raymond James

Price Target

$6

AI Analysis

2026-04-10

initiated

Strong Buy

Reason

Raymond James last night initiated coverage of Milestone Pharmaceuticals with a Strong Buy rating and $6 price target. At current share levels, the market is only assigning less than $100M in peak sales for Cardamyst in paroxysmal supraventricular tachycardia, the analyst tells investors in a research note. The firm says this equates to just a 2% penetration into the 2M patient population. Raymond James believes Cardamyst \"has all the fundamentals for a successful launch.\"

Raymond James

Tiago Fauth

Strong Buy

initiated

$6

2026-04-09

Reason

Raymond James

Tiago Fauth

Price Target

$6

2026-04-09

initiated

Strong Buy

Reason

Raymond James analyst Tiago Fauth initiated coverage of Milestone Pharmaceuticals with a Strong Buy rating and $6 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MIST

Unlock Now

Valuation Metrics

The current forward P/E ratio for Milestone Pharmaceuticals Inc (MIST.O) is 0.00, compared to its 5-year average forward P/E of -2.81. For a more detailed relative valuation and DCF analysis to assess Milestone Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.81

Current PE

0.00

Overvalued PE

-1.72

Undervalued PE

-3.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-1.81

Current EV/EBITDA

-0.71

Overvalued EV/EBITDA

-0.76

Undervalued EV/EBITDA

-2.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

45.54

Current PS

8.47

Overvalued PS

136.20

Undervalued PS

-45.12

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

penny stocks that are showing buy signals

Intellectia · 70 candidates

Market Cap: 100.00M - 500.00MRegion: USPrice: $1.00 - $5.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceCrossAboveMA20, PriceAboveMA200Week Price Change Pct: $-100.00 - $100.00Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Milestone Pharmaceuticals Inc

209.45M

Ovid Therapeutics Inc

392.68M

Codexis Inc

200.82M

Zentalis Pharmaceuticals Inc

195.77M

Invivyd Inc

381.79M

Agenus Inc

161.27M

most bullish ticker

Intellectia · 46 candidates

Analyst Consensus: Strong BuyTarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200Option Sentiments: BullishOne Week Rise Prob: >= 70

Ticker

Name

Market Cap$

Tarsus Pharmaceuticals Inc

2.78B

Journey Medical Corp

276.86M

Cytokinetics Inc

7.93B

Abcellera Biologics Inc

1.19B

Savara Inc

1.16B

Taysha Gene Therapies Inc

1.29B

undervalued penny stocks rn

Intellectia · 23 candidates

Market Cap: <= 1000.00MPrice: <= $5.00Beta: LowRisk, ModerateRiskWeekly Average Turnover: >= 4,000,000Pe Ttm: <= 8Ps Ratio: <= 0.50

Ticker

Name

Market Cap$

Alight Inc

831.79M

Sellas Life Sciences Group Inc

779.89M

Western Copper and Gold Corp

721.34M

Kosmos Energy Ltd

617.04M

Krispy Kreme Inc

597.84M

Lexinfintech Holdings Ltd

498.06M

Whales Holding MIST

Trading Trends

People Also Watch

Frequently Asked Questions

What is Milestone Pharmaceuticals Inc (MIST) stock price today?

The current price of MIST is 2.02 USD — it has decreased -3.81

What is Milestone Pharmaceuticals Inc (MIST)'s business?

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.

What is the price predicton of MIST Stock?

Wall Street analysts forecast MIST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIST is8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Milestone Pharmaceuticals Inc (MIST)'s revenue for the last quarter?

Milestone Pharmaceuticals Inc revenue for the last quarter amounts to 1.55M USD, decreased

What is Milestone Pharmaceuticals Inc (MIST)'s earnings per share (EPS) for the last quarter?

Milestone Pharmaceuticals Inc. EPS for the last quarter amounts to -0.16 USD, decreased -15.79

How many employees does Milestone Pharmaceuticals Inc (MIST). have?

Milestone Pharmaceuticals Inc (MIST) has 38 emplpoyees as of April 20 2026.

What is Milestone Pharmaceuticals Inc (MIST) market cap?

Today MIST has the market capitalization of 247.10M USD.